Beta-blocking agents in heart failure. Should they be used and how?
暂无分享,去创建一个
K. Swedberg | J. Cleland | W. Remme | E. Erdmann | F. Waagstein | M. Bristow | J. Cleland | F. Waagstein | E. Erdmann
[1] J. A. Bowers,et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.
[2] W. Abraham,et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. , 1996, Circulation.
[3] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[4] K. Swedberg,et al. Carvedilol for heart failure, with care , 1996, The Lancet.
[5] J. Port,et al. Cardiac adrenergic receptor effects of carvedilol. , 1996, European heart journal.
[6] J. Cohn,et al. Effect of carvedilol in severe chronic heart failure , 1996 .
[7] J. McMurray,et al. Clinical Trials Report: Cardiovascular & Renal: Ongoing and planned clinical trials in chronic heart failure and left ventricular dysfunction , 1995 .
[8] J. Floras,et al. Reductions in muscle sympathetic nerve activity after long-term metoprolol for dilated cardiomyopathy: preliminary observations. , 1995, British heart journal.
[9] H. Krum,et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. , 1995, Circulation.
[10] T. Yue,et al. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. , 1995, The Journal of pharmacology and experimental therapeutics.
[11] M. Quiñones,et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. , 1995, Circulation.
[12] D. Renlund,et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. , 1995, Journal of the American College of Cardiology.
[13] P. Grayburn,et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. , 1995, Journal of the American College of Cardiology.
[14] Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. , 1995, The American journal of cardiology.
[15] M. Metra,et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.
[16] P. Grayburn,et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. , 1994, Journal of the American College of Cardiology.
[17] L. Wilkins. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.
[18] F. Waagstein,et al. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. , 1994, Journal of the American College of Cardiology.
[19] W. French,et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. , 1994, Circulation.
[20] G. Plotnick,et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. , 1994, Journal of the American College of Cardiology.
[21] K. Swedberg,et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.
[22] M. Lomsky,et al. The link between acute haemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure. A study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol. , 1993, European heart journal.
[23] S. Douglas,et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. Cohn,et al. Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT II , 1993, Circulation.
[25] J. Skoularigis,et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. , 1993, Journal of the American College of Cardiology.
[26] D. Renlund,et al. beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. , 1993, The American journal of cardiology.
[27] Eric J. Eichhorn. Effects of bucindolol in heart failure. , 1993, The American journal of cardiology.
[28] M. Böhm,et al. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.
[29] E. Ohlstein,et al. Carvedilol Inhibits Vascular Smooth Muscle Cell Proliferation , 1993, Journal of cardiovascular pharmacology.
[30] J. Cleland,et al. Modification of atherosclerosis by agents that do not lower cholesterol. , 1993, British heart journal.
[31] M. Böhm,et al. Force-frequency relation in human heart failure. , 1992, Circulation.
[32] Hung‐Yuan Cheng,et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. , 1992, The Journal of pharmacology and experimental therapeutics.
[33] P. Poole‐Wilson,et al. Prevalence of heart failure in three general practices in north west London. , 1992, The British journal of general practice : the journal of the Royal College of General Practitioners.
[34] B. Parsons,et al. Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.
[35] G. Paolisso,et al. Metabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure , 1992 .
[36] R. Schwinger,et al. Alterations of the force-frequency relationship in the failing human heart depend on the underlying cardiac disease. , 1992, Basic research in cardiology.
[37] C. Lau,et al. Reduced stimulatory guanine nucleotide binding regulatory protein in idiopathic dilated cardiomyopathy. , 1991, American heart journal.
[38] D. Renlund,et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. , 1991, Circulation.
[39] M. Condorelli,et al. Effects of beta blockade on the relation between heart rate and ventricular diastolic perfusion time during exercise in systemic hypertension. , 1991, The American journal of cardiology.
[40] T. Hedner,et al. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. , 1991, Journal of the American College of Cardiology.
[41] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[42] A. Lenarda,et al. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy , 1991 .
[43] J. Hampton,et al. Exercise tolerance in patients with heart failure--how should it be measured? , 1991, European heart journal.
[44] J. Corbett,et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. , 1991, The American journal of cardiology.
[45] G. Sutton,et al. Epidemiologic aspects of heart failure. , 1990, American heart journal.
[46] I. Abrass,et al. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. , 1990, The American journal of cardiology.
[47] K. Jakobs,et al. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. , 1990, Circulation.
[48] S. G. Pollock,et al. Usefulness of bucindolol in congestive heart failure. , 1990, The American journal of cardiology.
[49] J. Port,et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. , 1990, Circulation.
[50] P. Grayburn,et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. , 1990, Circulation.
[51] T. Kawada,et al. Adrenoceptor-Blocking Activity and Cardiohemodynamic Effects of Carvedilol in Animals , 1990, Journal of cardiovascular pharmacology.
[52] G. Mancia. Sympathetic activation in congestive heart failure. , 1990, European heart journal.
[53] C. Lau,et al. Improvement in exercise performance and hemodynamics by labetalol in patients with idiopathic dilated cardiomyopathy. , 1990, American heart journal.
[54] D. Renlund,et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. , 1990, The American journal of medicine.
[55] Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. , 1990, Lancet.
[56] K Caidahl,et al. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. , 1989, Circulation.
[57] J. Herlitz,et al. Early use of metoprolol and serum potassium in suspected acute myocardial infarction. , 1989, International journal of cardiology.
[58] R. Reneman,et al. Cardiovascular effects of dl-nebivolol and its enantiomers--a comparison with those of atenolol. , 1988, European journal of pharmacology.
[59] W. Schmitz,et al. INCREASE IN MYOCARDIAL Gi-PROTEINS IN HEART FAILURE , 1988, The Lancet.
[60] W. Baumgartner,et al. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. , 1988, The Journal of clinical investigation.
[61] M. Wilén,et al. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. , 1988, JAMA.
[62] J. Cleland,et al. Arrhythmias, catecholamines and electrolytes. , 1988, The American journal of cardiology.
[63] R. van der Does,et al. Acute Hemodynamic Effects of the Vasodilating and &bgr;‐Blocking Agent Carvedilol in Comparison to Propranolol , 1987, Journal of cardiovascular pharmacology.
[64] M. Bristow,et al. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. , 1986, Circulation.
[65] N. Rehnqvist,et al. Effect of metoprolol in postinfarction patients with increased heart size. , 1986, European heart journal.
[66] R. Byington,et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. , 1986, Circulation.
[67] G. Stokes,et al. STUDIES ON THE VASODILATOR ACTIONS OF BUCINDOLOL IN THE RAT , 1986, Clinical and experimental pharmacology & physiology.
[68] R. Gunnar,et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. , 1985, Circulation.
[69] R. Peto,et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.
[70] P. Vanhoutte,et al. Pharmacology of bucindolol in isolated canine vascular smooth muscle. , 1984, The Journal of pharmacology and experimental therapeutics.
[71] J. Federman,et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. , 1984, Journal of the American College of Cardiology.
[72] H. Ikram,et al. DOUBLE-BLIND TRIAL OF CHRONIC ORAL BETA BLOCKADE IN CONGESTIVE CARDIOMYOPATHY , 1981, The Lancet.
[73] K. Swedberg,et al. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. , 1980, British heart journal.
[74] K. Swedberg,et al. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. , 1980, British heart journal.
[75] K. Swedberg,et al. PROLONGATION OF SURVIVAL IN CONGESTIVE CARDIOMYOPATHY BY BETA-RECEPTOR BLOCKADE , 1979, The Lancet.
[76] E. Varnauskas,et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.
[77] F. Waagstein,et al. Apex cardiogram and systolic time intervals in acute myocardial infarction and effects of practolol. , 1974, British heart journal.
[78] E. Braunwald,et al. The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. , 1966, Annals of internal medicine.